The latest response from Shen Teng, who was seriously ill, came: Everything is fine!

1905 movie network news Recently, it has been widely rumored on the Internet that due to serious illness, there are still many operations to be done, and it is about to retire, which has aroused everyone’s concern. On the evening of April 28th, Shen Teng sent a message on social media to respond:Everything is fine recently. Thank you for your concern.


Earlier, some netizens met Shen Teng in Japan and shared photos of Reuters on social platforms. Subsequently, Shen Teng suffered from cervical spondylosis and lumbar spondylosis, and the rumor that he was going to Japan for surgery was rampant. Finally, it evolved into Shen Teng, which was seriously ill and was about to retire, which made netizens very worried. Fortunately, Shen Teng responded in time. In addition to saying that everything is fine, he also sent a few pictures to reveal himself.I am watching the new musical The Awakeing Age of our company, and I recommend it to you. I wish you a happy holiday. ".

The latest pure electric endurance test results of hybrid and extended-range models are released

On December 14th, recently, the results of the 2023 winter test of many popular new energy vehicles announced by Know Car Emperor caused controversy. Know Car Emperor held the winter test open day at Mohe at minus 40 degrees at 9: 00 today, and re-tested the plug-in/extended-range pure electric battery life, which was broadcast live all the time. Some car companies, media and user representatives were invited to the on-site experience supervision.

On the open day, the test models were Wangwang U8, Wenjie M7, Weipai Gaoshan, Lingke 08EM-P, Lantu FREE and Tengshi D9 DM-i, and the test rules were exactly the same as the previous tests.

The latest test results are as follows:

Latest test results

Previous test results

IT House noticed that the test results were somewhat unexpected. The LEICK 08EM-P only traveled 6.5km with pure electricity, while the boundary M7 only traveled 10.6km with pure electricity. The first car to quit was the Lectra 08, and it only ran 6.5 kilometers before the engine stepped in. The second car to quit was the car named "Wenjie M7". When the power battery was 31%, the engine intervened, and the pure electricity ran 10.6 kilometers. The third one to quit is 17.4 kilometers from Weipai Mountain. When the power is 29%, the engine intervenes. The fourth car was Tengshi D9, with 24% engine involved, and the pure electricity ran 18.9 kilometers. The fifth quitter was Lantu FREE, who ran 36.8 kilometers. Finally, I looked up at U8, ran 65.5 kilometers, and the engine intervened when the power was 23%.

According to media reports such as Red Dot in the comprehensive automobile market, one reason why the test results of the open day will be lower than the previous test is that the ambient temperature is lower. Before the test officially started, the host who knew the car emperor also admitted frankly.Because today’s temperature is too low, it is too different from the previous test setting of MINUS 20 degrees, and the test results are for reference only.The test results are relatively objective, "There is no absolute fairness in this world". Another reason is that the preparation time is longer, reaching 81 minutes.

One of the focuses of the test dispute is the preparation of the vehicle, because repeatedly opening and closing the door will have a great impact on the temperature inside the vehicle and increase the power consumption of the air conditioner. The host who knows the car emperor said that this move is to make the test completely transparent and ensure that the variables such as electric mode and air conditioning temperature are basically the same. So can we not turn on the electricity during the servicing period? Judging from the actual experience of the field representative, it is difficult to complete the maintenance without air conditioning, because the ambient temperature has reached MINUS 40 degrees Celsius on the day of the test.

It is worth mentioning that the live broadcast of Zhiche Di’s winter test in Tik Tok and his own App has closed barrage comments. And at 10: 20, the live broadcast was suddenly interrupted.

It is worth mentioning that the winter test is only the extreme test under extremely cold conditions, not the normal endurance performance of daily driving environment. And the difference between the two test results also shows that the test results are full of uncertainty.

The Korean remake of Rene Liu’s Later Us was released in 2023.

1905 movie network news  On June 15th, SHOWBOX, a Korean film distribution company, announced a remake of the film directed and starring, which is expected to be released in 2023.


It was released in China on April 28, 2018. After the release, it won the single-day box office champion for 12 consecutive days, becoming the box office champion in May 1st in 2018, and finally won 1.36 billion box office. After landing in South Korea in 2018, "Later Us" was deeply loved by local audiences, and scored more than nine points in Korean movie portals.

Rene Liu’s version of Later Us tells the story that college student Lin Jianqing and fellow countryman Fang Xiaoxiao met on the train in Spring Festival travel rush, and started the struggle life of drifting north together. They experienced love, breakup and miss, and they met again ten years later.



The insured entrance is online! The maximum guarantee is 3.3 million! "Health and Buddha Medical Insurance" is coming.

Waiting for a year, finally returning!

"Health and Buddha Medical Insurance" in 2024

Officially launched today! ! !

Before enrollment

Let’s take a look at the answers to these questions first

Question 1

What is the nature of "Health and Buddha Medical Insurance"?

"Health and Buddha Medical Insurance" is a commercial medical insurance product approved by the Foshan Municipal People’s Government and jointly directed by Foshan Medical Insurance Bureau, Foshan Supervision Branch of the State Financial Supervision and Management Bureau, Foshan Financial Work Bureau and Foshan Social Insurance Fund Management Bureau. According to Foshan’s medical and living standards, it is highly connected with Foshan’s basic medical insurance and serious illness insurance policies, improving the city’s medical security level, effectively reducing the medical expenses burden of people suffering from major diseases, and providing millions of insurance coverage at inclusive prices to improve the health of Foshan residents.

Question 2

Which insurance companies underwrite "Health Buddha Medical Insurance"?

"Health Buddha Medical Insurance" was jointly underwritten by six insurance companies. Among them, China Life Insurance Co., Ltd. Guangdong Branch is the main underwriting company; It is jointly underwritten by China People’s Property Insurance Co., Ltd. Guangdong Branch, China Pacific Property Insurance Co., Ltd. Guangdong Branch, China Ping An Property Insurance Co., Ltd. Guangdong Branch, China United Property Insurance Co., Ltd. Guangdong Branch and Taiping Property Insurance Co., Ltd.

Q 3

I bought "Health Buddha Medical Insurance" this year. Do I need to buy it again next year?

The guarantee period of "Health Buddha Medical Insurance" is one year, so if you buy "Health Buddha Medical Insurance" this year, you need to buy it again next year. If the insured who pays through the medical insurance account checks "Auto Re-insurance" in the enrollment interface, he will agree to participate in the subsequent annual "Health Buddha Medical Insurance" by default and authorize the system to automatically handle the enrollment and payment procedures.

Q 4

Who can participate in "Health Buddha Medical Insurance"?

Persons who meet one of the following conditions can apply for "Health-Buddha Medical Insurance" commercial medical insurance according to the relevant policies and regulations in accordance with the principle of voluntariness (no age limit, no previous illness limit):

1 Foshan basic medical insurance insured;

2. Foshan registered residents who participate in the basic medical insurance in other overall plans;

3. Other new citizens who have participated in the basic medical insurance as a whole and hold a valid residence permit in Foshan as of March 31, 2024;

4. Foshan students who have participated in the basic medical insurance as a whole in other places;

5. Other high-level talents in this city who participated in the basic medical insurance as a whole and were selected into the national, provincial and municipal talent plans at all levels, as well as all kinds of talents in this city who hold Guangdong Talents Excellent Guangdong Card and Foshan Talents Green Card;

6 by the relevant departments of this Municipality identified as courageous people within the administrative area of this Municipality.

7 other medical security system to protect the personnel.

During the insurance period, the insurance contract is invalid for those who are not in line with the actual situation or the insurance conditions of "Health Buddha Medical Insurance", do not assume the insurance responsibility and return the full premium paid.

Q 5

What is the coverage of "Health Buddha Medical Insurance"?

The protection of "Health Buddha Medical Insurance" covers: compensation for personal medical expenses within the scope of medical insurance catalogue, compensation for personal expenses outside the scope of medical insurance catalogue, compensation for self-funded drugs for specific diseases, compensation for ultra-high medical expenses, and compensation responsibility for high medical expenses in general outpatient departments.

Health management value-added services:

First, early cancer screening

Second, medical services

Third, health services

Fourth, life service

(The details and implementation time of the above value-added services are subject to the announcement of "Health Buddha Medical Insurance" WeChat WeChat official account. )

Question 6

You already have medical insurance, do you still need to buy "Health Buddha Medical Insurance"?

Basic medical insurance can’t cover all the medical expenses of the insured. After being reimbursed by medical insurance, the insured still has to bear the remaining medical expenses.

"Health and Buddha Medical Insurance" is closely linked with basic medical insurance. After medical insurance reimbursement, the insured’s medical expenses can not only continue to reimburse the remaining compliant medical expenses, but also cover the self-funded medical compensation for specific diseases, effectively alleviating the economic pressure caused by serious diseases to the insured. In order to provide themselves with more health insurance, it is recommended that all eligible insured persons actively purchase a "Health Buddha Medical Insurance".

Q 7

Is there any conflict between "Health Buddha Medical Insurance" and other commercial health insurance? What’s the difference with other commercial health insurance?

There is no conflict. The medical expenses incurred by the insured can be claimed by different commercial health medical insurance products, but the total amount of compensation accumulated after multiple claims will not exceed the total medical expenses of the insured. The coverage of "Health Buddha Medical Insurance" is in parallel with the protection of other commercial medical health insurance. After medical insurance reimbursement and other insurance products claim, you can apply for compensation from "Health Buddha Medical Insurance".

The difference between "Health Buddha Medical Insurance" and other commercial medical insurance lies in:

(1) Age of insurance: "Health Buddha Medical Insurance" has no age limit for the insured, and other commercial medical insurance generally has an age limit for the insured.

(2) Past illness: Insured persons with past illness can also apply for "Health Buddha Medical Insurance". Medical expenses arising from past illness can be claimed normally, while other commercial medical insurance does not cover the insured with past illness.

(3) Waiting period: There is no waiting period for "Health Buddha Medical Insurance", and other commercial medical insurance generally has a waiting period of 30 days or more.

(4) Insurance premium: "Health Buddha Medical Insurance" does not distinguish between age and sex, and the unified price is 185 yuan/person/year. The insurance premium of other commercial medical insurance is generally differentiated by age and sex, and the older you are, the higher the premium is.

Question 8

Insurance and guarantee time

Insurance time:

March 21, 2024 to April 30, 2024

Guarantee time:

00: 00 on January 1, 2024 to 24: 00 on December 31, 2024.

You can pass

"Foshan Release" WeChat WeChat official account

Insure

Method 1: Send the keyword "Buddha Medical Insurance" in the background, and click the link below to participate in the insurance.

Method 2: Click on the menu bar [Convenience Interaction]-[Health Buddha Medical Insurance] to participate in the insurance.

·

Recommended reading

Found a very small photo graffiti! It is very compatible with the vernal equinox. In 2024, "Health and Buddha Medical Insurance" came! Treatment optimization +5! Beneficiaries +2! Value-added health management!

Original title: "The insured entrance is online! The maximum guarantee is 3.3 million! "Health Buddha Medical Insurance" is coming "

Read the original text

The highest 600 yuan! This allowance is available every month →

I wonder if there are any friends like Xiaoyun.

Want to retire early at a young age

Live an old-age life

Speaking of providing for the aged, you know that in Shanghai.

Can I enjoy comprehensive old-age allowance after I reach the age of 65?

Xiaoyun is here for everyone.

Finishing the detailed rules and standards.

For everyone to collect and forward ~

What is the comprehensive old-age allowance?

Comprehensive old-age allowance is an old-age welfare system initiated by Shanghai in China. According to the Notice of the Shanghai Municipal People’s Government on Establishing a Comprehensive Allowance System for the Elderly, it is clear that the elderly aged 65 and above who are registered in this city according to different age groups will receive monthly old-age allowances ranging from 75 yuan to 600 yuan. The older they are, the higher the allowance standard will be.

What is the standard of allowance?

How to apply for allowance?

When will the allowance be paid?

Look at the answer from the Civil Affairs Bureau ↓

01. How can I apply if I meet the requirements?

Eligible elderly people can apply for allowances to the community affairs acceptance service center nearby. Older people who are about to turn 65 can apply one month in advance.

02. What is the distribution route?

The comprehensive allowance for the elderly is issued through the Shanghai Senior Citizen Card. Apply for the Shanghai Respect for the Elderly Card at the same time as applying for the comprehensive allowance for the elderly. Respect for the elderly card is a bank debit card with financial function and senior citizen preferential treatment voucher function. When the elderly apply, they can choose one of the six commercial banks, namely China Industrial and Commercial Bank, China Agricultural Bank, China Construction Bank, China Postal Savings Bank, Shanghai Bank and Shanghai Rural Commercial Bank, as the issuing bank of their own comprehensive elderly allowance.

03. When will the comprehensive old-age allowance be paid?

The allowance is paid quarterly. On the 15th of the first month of each quarter (that is, January, April, July and October), the allowance for the current quarter will be paid to the senior citizen’s card.

In addition to the comprehensive old-age allowance, eligible Shanghai residents can also enjoy these subsidies and benefits.

It’s about the money bag

Let’s see if there are any omissions.

Shanghai Trade Union Welfare

Shanghai trade union members have new benefits to receive for free.

City Hotel Housing & Catering Discount

Hungry? Big red envelopes?

If you need to join the club, you can APPly through the "Join the Citizen Cloud" app [I want to join the club] service.

If you are already a member of the Shanghai Trade Union, you can get it free of charge through the "With the Bid Citizen Cloud" APP [Trade Union Services-Member Benefits], and you can enjoy the rights by presenting the Shanghai Trade Union electronic membership card offline.

Subsidies for older unemployed jobs

Open the "Apply for Citizen Cloud" APP, search for "Subsidies for Older Unemployed Jobs" on the home page, click [Apply for Subsidies for Older Unemployed Jobs] or directly scan the QR code in the figure below, and enter the page and follow the prompts to apply.

Transportation allowance for the disabled

Open the "With the Bid Citizen Cloud" APP, search for "Disabled People’s Transportation Subsidy" on the home page, click [Disabled People’s Transportation Subsidy Application] or directly scan the QR code in the figure below to enter the application.

The content and pictures of the article come from | Shanghai Civil Affairs. Please contact the original author for reprinting and authorization.

The goal of improving the ecological environment quality was successfully completed.

  Source: Cartography of Ministry of Ecology and Environment: Andy.

  Beijing, 18 Feb (Reporter Liu Yi, Kou Jiangze) The reporter learned from the recently held National Conference on Ecological Environment Protection that in 2022, the construction of beautiful China was solidly promoted, the national discharge of major pollutants continued to decline, the goal of improving the ecological environment quality was successfully completed, and the ecological environment protection work achieved hard-won new results.

  According to the Ministry of Ecology and Environment, in 2022, 25 new cities across the country were included in the scope of clean heating support in the northern region, and the ultra-low emission transformation of 210 million tons of crude steel production capacity and the rectification of more than 46,000 outstanding volatile organic compounds were completed. We will continue to investigate and rectify the sewage outlets of the Yangtze River, the Yellow River and the Bohai Sea into the sea, start the investigation and evaluation of the pollution situation of mines left over from the history of the Yellow River Basin, promote the remediation of black and odorous water bodies in county towns and county-level cities, delimit township-level centralized drinking water source protection zones, and implement actions to improve the water quality of rivers entering the sea. Carry out actions to prevent and control the source of heavy metal pollution such as cadmium in agricultural land soil. Environmental improvement in 16,000 administrative villages has been completed nationwide. The construction of a "waste-free city" was launched in an all-round way, and 14 new pollutants were included in the key control list.

  According to reports, in the past 10 years, China has continued to fight the defense of blue sky, clear water and pure land, and the prevention and control of pollution has advanced in depth, and the improvement of ecological environment quality has achieved remarkable results. The average concentration of PM2.5 in key cities in China decreased by 57%, and the concentration of PM2.5 in cities at prefecture level and above fell below the first-stage transition value of 35 μ g/m3 determined by WHO for three consecutive years from 2020 to 2022. In 2022, the proportion of days with excellent air quality in cities at prefecture level and above reached 86.5%, making China the country with the fastest improvement rate of air quality in the world.

  In the past 10 years, the proportion of excellent surface water quality in China has increased by 23.8 percentage points, reaching 87.9%, which is close to the level of developed countries. For three consecutive years, the main stream of the Yangtze River reached Grade II water quality, and the main stream of the Yellow River reached Grade II water quality for the first time. The proportion of excellent water quality in coastal waters nationwide increased by 17.6 percentage points. Black and odorous water bodies are basically eliminated in the built-up areas of cities at prefecture level and above. In the past 10 years, China has successfully achieved the goal of "zero import" of solid waste, effectively controlled the environmental risks of soil and groundwater, and significantly improved the rural ecological environment.

  The Ministry of Ecology and Environment said that the prevention and control of environmental pollution will be further promoted in 2023.

  Advance the defense of the blue sky — — Promote the construction of environmental infrastructure such as natural gas pipeline network, promote clean heating in the northern region in an orderly manner according to local conditions, promote ultra-low emission transformation and comprehensive treatment of key industries, carry out in-depth treatment of volatile organic compounds, deepen joint prevention and control of air pollution in key areas, and implement noise pollution prevention and control action plans.

  Advance the defense of clear water — — We will promote the pilot project of water ecological assessment in the Yangtze River basin, fully implement the rectification of tributaries entering the Yellow River, organize the rectification of black and odorous water bodies in cities (including counties), consolidate and improve the level of drinking water safety, and comprehensively strengthen the supervision of mariculture, marine engineering, marine dumping and marine garbage.

  Advancing the Defence of Pure Land — — Strengthen the implementation effect of major projects to control the source of soil pollution, strengthen the control of soil pollution in production enterprises and closed relocation enterprises, delimit key areas for groundwater pollution prevention and control, and continue to promote rural environmental improvement. Strengthen the treatment of solid waste and new pollutants, further promote the high-quality construction of "waste-free cities", further promote the reform of strengthening the supervision, utilization and disposal capacity of hazardous wastes, start the pilot project of new pollutant treatment, and carry out in-depth prevention and control of heavy metal pollution in key industries.

The front desk tests the water first: what about the AI that has launched many generative AI programs and knows more about Chinese culture?

  It is generally believed in the industry that if 2023 is a "wild year" for generative artificial intelligence technology, then 2024 is expected to be the "first year" for the great development of artificial intelligence applications. With the development of AI big model and various text generation, Wensheng pictures and Wensheng video tools all the way this year, the global media industry will also usher in all-round changes in the way of content production, dissemination and consumption. The revolutionary breakthrough of technology presents the creator with a "magic pen". How should the media seize the opportunity to become a "good horse" who makes good use of this wonderful pen?

  On February 26th, China’s first Wensheng video AI series was produced by the Central Radio and Television General Station.200 episodesThe animated film "Ode to a Thousand Years" was launched. The first AI mini-drama "The Myth of China" and the first AI translated English series of micro-documentaries "The Story and the Story" were also released.This is a set of concrete practices for the Headquarters to actively explore the innovative application of generative artificial intelligence technology in the media field, seize a new round of scientific and technological revolution and industrial transformation, and strive to seize the commanding heights of future industrial competition to empower the cultural industry and international communication.

  With the empowerment of AI, the future of the media industry has come. How to tell Chinese cultural stories well through generative AI? How to make the new quality productivity become the biggest increment of the high quality development of the main station? Let’s start with a series of AI practices led by the reception desk.

  AI big model with China aesthetic.

  Let it sing, and ask for its friendly voice. The communication between people begins with the communication of language. Similarly, the communication between creators and AI has to go through the communication process of "meeting friends with literature".

  In July 2023, the Headquarters and Shanghai Artificial Intelligence Laboratory released the "CCTV Listening Media Model", which was first applied to the creation of Ode to a Thousand Years.In the first season of Ode to a Thousand Years, the latest technological achievements such as controllable image generation, dynamic character generation and literary video were comprehensively used.Six well-known Tang poems, such as Ode to Goose, Crossing the Old Man’s Village and a farewell to meng haoran on his way to yangzhou of the Yellow Crane Tower, were transformed into beautiful national animation.

  The program creation team uses a large number of Chinese paintings and ancient poems as training materials to communicate with the AI ? ? model. After countless collisions between artistic creation language and code language,"CCTV listening to the media model" has a unique style and strength — — China’s aesthetics.It can accurately understand the traditional cultural words such as "national style, Tang Dynasty, freehand brushwork and meticulous painting", and generate fine art materials such as meticulous painting and ink painting, so as to reproduce the artistic conception and beauty of poetry to the maximum extent.

  The ratings of the first six episodes of Ode to a Thousand Years’ Poetry ranked first among all the cartoons on the satellite channel in China, reaching a total audience of 94.413 million people., the central video client’s live viewing volume reached 13.182 million person-times, and Weibo’s topic reading volume totaled 92.814 million person-times. Hundreds of mainstream media at home and abroad, including VOA, pay attention to the innovative practice of the reception desk. Many experts and scholars in the fields of science and technology, media and education expressed their support and affirmation.

  Many netizens commented that "AI has shaped a new mode of production, and Ode to a Thousand Years of Poetry has opened up the imagination of the industry." "When the AI ? ? big model meets the oriental aesthetics, China’s poetry is really ‘ Live ’ Get up "and" enter the smart primary and secondary school platform early, which is convenient for teachers and students to use "… …

  AI can also activate the imagination of more cultures. "Ode to a Thousand Years" has just started broadcasting. On February 29th, the artificial intelligence studio of the General Station and the Tsinghua University Yuan Universe Culture Laboratory jointly produced the "China Myth Series Mini-short Drama" and "Mending the Sky", which was released to creatively interpret the enduring code of Chinese civilization contained in myths and legends.This is the first full-process mini-drama of AI in China. Art, camera, video, dubbing and soundtrack are all completed by AI, which is another pioneering practice for the film and television application of AI technology.

  The key to Wensheng video is "text". Long-term infiltration in Chinese culture, repeated training and deep learning, the research and development of "CCTV listening to media model" is becoming more and more mature, the future program production cycle will be further shortened, and the fineness of works will be continuously upgraded. More and more "understanding" AI partners can not only save time and effort in film and television animation production, game development and advertising design, but also accelerate the development process of mature application of Wensheng video, business model expansion and overseas spread.

  How does AI improve the efficiency of international communication?

  The application practice of AI in many international communication scenes at the main station shows that AI-assisted production can not only greatly improve the efficiency of multi-language conversion and multi-platform distribution, but also realize authentic and loving cross-cultural interaction under the escort of man-machine collaboration.

  Question 1:

  Suppose you are an artificial intelligence. Today’s job is to translate a documentary in English. When a dragon talks seriously about how to "fine raise dragons" and talks about "Nagada in Northeast China" with his own accent, how should you deal with it?

  A: Note that to explain loong’s "ins and outs" clearly in a foreign language, you should not only translate it accurately and rigorously, but also speak it erudite and lovely.

  This documentary, named "The Story", is a series of loong-themed micro-documentaries translated by the Headquarters with the full AI process empowerment, and will be launched soon.The film effectively explores the efficient application scenario of the whole process of film and television translation of AI. Using AI technology, the whole translation process from voice recognition, text translation, voice cloning to track-splitting replacement has been completed, which highly restored the style of the original Chinese film and the "character dragon design" of narration.The accuracy of translation is ensured by man-machine cooperation, which greatly improves the efficiency of translation.

  In addition to the English version, the Spanish, Portuguese, Indonesian, Filipino and other versions of The Story, the multilingual version of Ode to a Thousand Years ago and other excellent programs have fully utilized the independent AI technology of the reception desk to assist in the translation. On March 10th, the English and Spanish versions of Ode to a Thousand Years’ Poetry were officially released on CGTN. At the same time, multilingual film and television translation will be included in the training plan of CCTV Listening to Media Model, which will help the construction of the national multilingual film and television translation base of the General Station and effectively improve the international communication efficiency of Chinese film and television culture.

  Question 2:

  There is a group of news reports that need to be translated in multiple languages and distributed overseas in the shortest time. Is there any way to quickly generate multilingual and batch video products?

  A: Yes.The main station makes full use of AI technology, and realizes the geometric progression growth of news output and broadcast quantity through the form of multi-language superposition and multi-platform distribution.For example, in a short period of one week, the series of English reports of Opportunity China: A First-line Economic Observation was transformed into nearly 100 multilingual video products in 10 languages, including Spain, France, Albania, Russia, Germany and Portugal, and broadcast on overseas platforms, which strongly refuted the so-called "China economic summit theory" in the United States and the West.

  These products have clear and bright pictures and real and natural sounds, which bring surprises to overseas netizens. A Russian netizen left a message: "I am also surprised that this Chinese speaks Russian without any accent. It turned out to be AI, which is really awesome!"

  It is not only the reported multilingual conversion, but also the AI virtual digital avatars of several CGTN hosts. The production mode of generating video through manuscript input saves the real-life recording link, shortens the shooting and material export work that originally took up to 2 hours to only 5 minutes, and greatly improves the upper limit of single-person single-day video output.

How does the AI track run steadily and accelerate?

  There is a view that the development of artificial intelligence, especially the exponential growth of generative AI, has shortened the unit of measurement of technological change from years and months to days, and may even be calculated in hours and minutes in the future. If you don’t advance, you will retreat, and if you advance slowly, you will retreat. All in or wait and see? For the media industry, it is more critical to find a way to increase productivity through technological innovation.

  How does the media industry run out of "acceleration" on the AI ? ? track? In the development and application of generative AI technology, there are two main development concepts that the main station has always adhered to.

  On the one hand, we should insist on original research, and strive to build an internationally leading model of Wensheng video with China cultural characteristics.Compared with Sora’s vivid visual effects, the AI animation of programs such as Ode to a Thousand Years ago has some problems, such as blurred background and insufficient coherence of characters’ actions, which shows that there is still a certain gap between the video generation model independently developed by China and the world’s advanced technology. However, at present, the Chinese corpus accounts for only 1.3% of the global large-scale model data training set, and the characteristics of China are obviously insufficient. Facts show that insisting on original research is the fundamental to promote the development of independent general artificial intelligence in China.

  In 2023, the Headquarters and Shanghai Artificial Intelligence Laboratory jointly established the "China Large Model Corpus Database Alliance".On the understanding and expression of Chinese culture, and the integration with the actual production process created by the media, the AI practice led by the General Desk has unique China aesthetic and Chinese cultural characteristics.

  The main station has a rich and standardized audio-visual corpus such as China Audio-visual Archive, and all materials have been tagged, which is also the largest Chinese audio-visual corpus in the world.Training with the massive high-quality audio-visual data and professional media creation knowledge of the main station, the model is expected to grow rapidly in continuous actual combat and embark on a differentiated road of China’s technological development.

  On the other hand, to do a good job in platform construction, we should promote the integration of "Industry-University-Research" and continuously optimize the safe and reliable AIGC technology platform.The core of big model breakthrough lies in algorithm, computing power and data. The Headquarters will work with Shanghai Artificial Intelligence Laboratory to build an independent and controllable domestic intelligent computing platform, and further promote the newly established large-scale model research and development community and artificial intelligence studio construction. Linking the upstream and downstream of the industrial chain, the first-class scientific research institutions, universities and enterprises in the United Nations will cooperate in the fields of scientific research, demand application, safe development and industrial ecology.

  Since the establishment of the main station, the whole stage has always maintained a state of being in danger, breaking through difficulties and seizing opportunities. Beginning in 2019, the head office leaders visited Shanghai Jiaotong University and other institutions to discuss the high-quality development of the artificial intelligence empowerment head office and set up relevant cooperative research institutions. After the Sora Wensheng video appeared, the leader of the main station asked the whole station to pay close attention to it and keep a close eye on it to prevent a complete defeat overnight.Artificial intelligence does not make creativity "fall from the sky", but opens up new application scenarios for "golden ideas" from all walks of life, providing innovative infrastructure and auxiliary capabilities.

  After several years of practice, the Headquarters has continuously deepened the development strategy of "5G+4K/8K+AI", and at the same time vigorously promoted the innovation of media technology, transformed the new quality productivity into more refreshing quality programs. A series of practical achievements about generative AI made by the Headquarters are not a temporary follow-up "early adopters", but a series of "products made by the Headquarters" and "golden business cards" of Chinese culture. How will the AI road of the main station continue to break through the boundaries of media technology and create new imagination and fresh experience about Chinese culture for the global audience? I believe there are more scenic spots ahead.

The first preview of Xiaomi SU7 Ultra production version was released on October 29th.

Lei Jun released a brand-new official map of Ultra production in Weibo on October 28th. This is the first official picture of the production version, from which we can see the changes of many production models.

From the previous photos of the prototype of Xiaomi SU7 Ultra, it can be found that the prototype has a huge GT tail. Exaggerated diffusers and side skirts, tires are not street tires but hot-melt tires dedicated to the track. These exaggerated details are really in line with the identity of the prototype, and everything is for faster lap times.

Obviously, these kits can’t get on the road legally, and this preview also confirms this. The preview mainly shows the tail and side details of the production model, and many differences can be clearly found. First of all, the oversized GT tail wing was replaced by a more conservative small tail wing, and the wind knives on both sides of the prototype were also replaced by a folding design.

In addition, the rear enclosure has been replaced by the production version of ordinary SU7, and the giant diffuser below has disappeared. It seems that the side skirts and side air ducts have also been replaced with the style of ordinary SU7.

It can be seen that this prototype mass production has made many compromises in appearance, and a large number of aerodynamic kits have also been replaced.

However, the V8s motor used in the prototype should be retained, and the acceleration of 0-100km/h should still be expected to run within 2s by using the three-motor plus four-wheel drive.

The new car will be unveiled at the Xiaomi new product launch conference on October 29, and the actual performance can be expected.

The first batch of national parks in China was formally established Northeast Tiger and Leopard National Park | The largest settlement and breeding area of wild Siberian tiger and leopard in China.

CCTV News:Northeast Tiger and Leopard National Park, which spans Jilin and Heilongjiang provinces, is located in the center of Asian temperate coniferous and broadleaved mixed forest ecosystem, adjacent to Russia and North Korea. It is the largest and only settlement and breeding area of wild Siberian tiger and leopard population with breeding families in China. With various vegetation types and relatively complete ecological structure, the park is a typical representative of temperate forest ecosystem and a model of cross-border cooperation and protection.

It is understood that since the pilot of the Northeast Tiger and Leopard National Park in August 2017, the ecosystem in the pilot area has been protected, restored and managed as a whole, and the ecosystem with tigers and leopards as its flagship species has shown a good recovery trend, embarking on a new path in which important natural resource assets across provincial administrative regions are directly exercised by the central government. According to the latest data from the Northeast Tiger and Leopard National Park Administration, the number of wild Amur tigers and Amur leopards in the Northeast Tiger and Leopard National Park has also increased from 27 and 42 at the beginning of the pilot in 2017 to 50 and 60 respectively, and more than 10 newly bred cubs and more than 7 cubs have been monitored.

The FDA’s annual inventory came, and 37 innovative drugs were approved! The domestic new drug "going out to sea" was a success, and these two domestic pharmaceutical companies lit up.

Recently, the FDA released the annual report on new drugs in 2022. The data shows that the FDA approved 37 innovative drugs to be listed last year, with the number reaching a new low of nearly six years, of which nearly 50% have been listed in China or are in the review stage. The FDA promotes and speeds up the evaluation of new drugs in various ways through "multi-pronged approach". In 2022, a number of domestic innovative drugs "went out to sea" to break through the FDA, and the results were "mixed". Two domestic innovative drugs were approved by the FDA and four hit a wall.

Figure 1: Number of new drugs approved by FDA in recent ten years

45491674084710448

Source: FDA2022 Annual Report on New Drugs (New Drug Therapy Approvals 2022).

37 innovative drugs were approved, and 18 accelerated the entry into the China market.

Recently, the Center for Drug Evaluation and Research (CDER) of FDA released the annual report of new drugs in 2022. In 2022, the FDA approved the listing of 37 innovative drugs, with the number reaching a new low of nearly six years. Among the approved innovative drugs, 20 (54%) belong to "first-in-class" innovative drugs, and 20 (54%) are drugs for rare diseases.

As the benchmark of global pharmaceutical supervision, FDA has approved 28 new drugs (76%) in the first round, and 25 (68%) in the United States before other countries.

In 2022, FDA promoted and accelerated the evaluation of new drugs in various ways through "multi-pronged approach". Twelve (32%) were identified as fast-track, 13 (35%) were identified as breakthrough therapeutic drugs, 21 (57%) were identified as priority review, and 6 (16%) were accelerated for approval. CDER used one or more accelerated development and review methods for 24 (65%) of all new drugs approved in 2022.

Table 1: Innovative Drugs Approved by FDA in 2022

98651674084710515

29821674084710717

9221674084710820

77661674084710920

Source: FDA website, intranet database.

In recent years, more and more attention has been paid to innovative drugs in China. In 2022, innovative drugs approved in the United States are also running into the China market at "China speed" to solve the unmet health needs of more China patients. According to statistics, at present, 18 (49%) innovative drugs are at the stage of clinical application and above in China. Among them, four innovative drugs, namely, abcixinib, voronoxan, benvimod and pessolizumab, have been approved for marketing, while otconazole and deuterium colexitinib are in the application stage, while nine innovative drugs are in clinical phase III, one in clinical phase I and two in clinical application.

Table 2: Research and Development of Innovative Drugs in China

40401674084710995

Source: Minenet database

Two domestic innovative drugs "went to sea" successfully, and legendary creatures actively expanded their territory.

In 2022, a number of domestic innovative drugs "went out to sea" broke through the FDA, and Sidakio Orense and Benvimod returned gratifying news and were successfully approved for listing.

On February 28th, 2022, the BCMA CAR-T drug Cedactylosin developed by Kingsley’s Legendary Biology was approved by FDA for the treatment of relapsed or refractory multiple myeloma. Cedactylosin became the first cell therapy product approved by FDA in China and the second CAR-T cell immunotherapy approved for BCMA in the world. This is a beautiful "turnaround" after the FDA announced the tightening of China’s listing policy for innovative drugs, which means that China has officially entered the world’s first-line position in the field of cell therapy.

After the successful listing in the United States, Sida Chiolense also extended its listing territory to the European Union and Japan in 2022. In May, 2022, the European Commission (EC) has granted conditional marketing permission to Cedactylosin for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three treatments in the past, including immunomodulatory drugs, proteasome inhibitors and anti-CD38 antibodies, and the last treatment showed disease progression. In September, 2022, the Japanese Ministry of Health, Labor and Welfare approved Cedactylosin for the treatment of adult patients with recurrent or refractory multiple myeloma. At present, in China, Sida Chiolense is in the stage of applying for listing.

Figure 2: Global R&D progress of Sida Chiolense.

87341674084711042

77311674084711093

31201674084711159

On May 24th, 2022, Dermavant Sciences announced that the FDA had approved the marketing of VTAMA (Benvimod, 1%) cream for the local treatment of adult plaque psoriasis. Benvimod, developed by Tianji Medicine, a domestic enterprise, is the first-in-class new drug with independent intellectual property rights.

In 2012, GSK obtained the overseas development right of Benvimod with a down payment of nearly $200 million. In July 2018, GSK announced that it would sell the overseas development right of Benvimod to Dermavant for $330 million.

As early as May 2019, Benvimod was approved to be listed in China as a "Class 1 new drug" for adults with mild to moderate stability psoriasis vulgaris suitable for local treatment. So far, benvimod is the first innovative drug approved by the FDA after it was approved for marketing in China.

Figure 3: Global listing of Benvimod

50321674084711209

The road to "going out to sea" is not smooth. Cinda Bio and Junshi Bio … find another way out.

The road to "going out to sea" was not smooth sailing. In 2022, the innovative drugs of Cinda Bio, Junshi Bio, Hutchison Whampoa and Baekje Shenzhou all submitted their applications for listing in the FDA, but they were rejected by the FDA one after another.

Table 3: Drugs not approved by FDA in 2022

58801674084711274

In March, 2022, Cinda Bio announced that FDA refused to approve the listing application of new drugs for the first-line treatment of patients with non-squamous non-small cell lung cancer, including cindilizumab combined with pemetrexed and platinum chemotherapy. In its reply to Cinda Bio, FDA pointed out that the related product trials of Cinda Bio were only conducted in China, not global multi-center clinical trials, and the results were not applicable to patients in the United States due to the nature of a single country.

In May, 2022, Hutchison announced that the US FDA had not approved the application of Suo Fan tinib for the marketing of new drugs for the treatment of pancreatic and non-pancreatic neuroendocrine tumors. The reason for FDA’s rejection of Hutchison is similar to Cinda Bio’s. It thinks that the data package of Hutchison based on two successful China Phase III studies and an American bridging study is not enough to support the drug’s approval in the United States, and more international multi-center clinical trials representing American patients need to be included to support the approval in the United States.

In the same month, Junshi Bio’s application for the marketing of PD-1 antibody Treprilizumab received a complete reply from FDA, requesting a quality control process change. This process change was rejected because the facilities could not be inspected on site due to travel restrictions during COVID-19.

In July, 2022, Baekje Shenzhou announced that the FDA of the United States could not complete the required on-site verification work in China as scheduled due to travel restrictions related to the COVID-19 epidemic, so it would extend the completion time of the target review of the application for the new drug listing license for second-line esophageal squamous cell carcinoma. However, its partner Novartis revealed in the quarterly report that it had cancelled the listing application for the treatment of non-small cell lung cancer with tierellizumab in the United States.

In the face of the "ruthless" rejection of the FDA, Junshi Bio quickly made adjustment measures and resubmitted the application for the listing of Trepril monoclonal antibody to the US FDA. The FDA has set the date of PDUFA as December 23rd, 2022. Trepril monoclonal antibody is still in the approval stage, and there is no clear result. Hutchison Whampoa said that it is working with the FDA to evaluate the next step. Baekje Shenzhou is rumored to move to Europe, and it is expected that it will submit its first listing application in the EU in 2023. Cinda Bio announced at the end of the year that it had recovered the overseas rights and interests of Cindilizumab from its partner Lilly Pharmaceutical.

There are many cases of domestic innovative drugs failing to go to sea. On the one hand, FDA has high requirements for domestic pharmaceutical companies’ products going to sea. According to the FDA’s previous requirements for Cinda Bio, if the new PD-1 wants to be listed in the United States, it needs to compete with the existing standard therapies. And drug K has been approved for dozens of indications in the United States, and products with the same indications have to cross the mountain of drug K if they want to be approved. On the other hand, at present, how to conduct clinical trials of domestic innovative drugs overseas is still in the exploratory stage. These failed cases essentially reflect the doubts of foreign mature markets on the quality of clinical trials in China.

tag

2022 has passed, and the innovative drugs approved by FDA are the direction of global innovative drug research and development trends, leading the way for innovative pharmaceutical companies. For domestic innovative pharmaceutical companies, if they want their products to go abroad, there is no doubt that they should sum up their previous experience in innovating drugs in the FDA, always pay attention to the changes in the clinical pattern, and keep in touch with the FDA for clinical design. At the same time, we should improve our products from many dimensions, such as reflecting the innovation of products, meeting unmet clinical needs, improving drug accessibility, improving technology, selecting indications, and improving safety and efficacy.

Source: Minenet comprehensive database.

This article is an original manuscript, please indicate the source and author, otherwise the tort liability will be investigated.